Cx Precision Medicine

Executive Summary

Cx Precision Medicine (CxPM) is an AI-driven diagnostics company focused on enabling earlier detection of cognitive decline through its proprietary blood test, NeuroFirst™ Memory. Targeting individuals over 60 with memory complaints, the test aims to identify Alzheimer's disease and related dementias at an earlier, more treatable stage. CxPM's approach combines advanced biomarker analysis with machine learning to improve diagnostic accuracy and patient outcomes. The company's platform addresses a critical unmet need in neurodegenerative disease management, where early intervention can significantly alter disease progression. With an emphasis on non-invasive, cost-effective solutions, CxPM is positioned to disrupt the current diagnostic paradigm and expand access to timely, precise diagnosis. While still in early commercial stages, the company's technology has the potential to reduce healthcare burdens and improve quality of life for aging populations. CxPM's progress will depend on clinical validation, regulatory clearance, and market adoption within the competitive diagnostics landscape.

Upcoming Catalysts (preview)

• Q4 2026Publication of pivotal clinical validation data for NeuroFirst™ Memory60% success
• Q1 2027Partnership with major healthcare system or diagnostic lab40% success
• Q2 2027FDA breakthrough device designation or 510(k) submission30% success